State-law design-defect claims that turn on the adequacy of a drug's warnings are pre-empted by federal law under PLIVA. Inc. v. Mensing, which held that failure-to-warn claims against generic manufacturers are pre-empted by the Federal Food, Drug, and Cosmetic Act's prohibition on changes to generic drug labels.